Pyxis Oncology, Inc. (PYXS): Price and Financial Metrics

Pyxis Oncology, Inc. (PYXS): $4.83

0.14 (+2.99%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add PYXS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#176 of 362

in industry

PYXS Price/Volume Stats

Current price $4.83 52-week high $6.85
Prev. close $4.69 52-week low $1.35
Day low $4.74 Volume 573,311
Day high $5.09 Avg. volume 816,341
50-day MA $5.12 Dividend yield N/A
200-day MA $2.89 Market Cap 280.78M

PYXS Stock Price Chart Interactive Chart >


Pyxis Oncology, Inc. (PYXS) Company Bio


Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.


PYXS Latest News Stream


Event/Time News Detail
Loading, please wait...

PYXS Latest Social Stream


Loading social stream, please wait...

View Full PYXS Social Stream

Latest PYXS News From Around the Web

Below are the latest news stories about PYXIS ONCOLOGY INC that investors may wish to consider to help them evaluate PYXS as an investment opportunity.

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalitiesBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer (CMO), effective November 27, 2023. Dr. Kobayashi brings extensive

Yahoo | November 28, 2023

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immunotherapy antibody candidate): Phase 1 trial now focusing on NSCLC and other tumor types; data expected 2H 2024. Cash runway extended to early 2026 due to cost reductions and portfolio prioritization, allows for preliminary data readouts from PYX-201 and PYX-106

Yahoo | November 7, 2023

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four different assets have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego. “We look forward to presenting a trial-in-progress poster for PYX-201, our first-in-class a

Yahoo | September 27, 2023

Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology Inc

On September 13, 2023, Lara Sullivan, President and CEO of Pyxis Oncology Inc (NASDAQ:PYXS), sold 27,917 shares of the company.

Yahoo | September 14, 2023

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upcoming investment conferences. On September 6, 2023, members of the Pyxis Oncology executive team will host in-person 1x1 meetings with investors during the 2023 Wells Fargo Healthcare Conference in Boston. To schedule a meeting, please reach out to your Wells Far

Yahoo | August 31, 2023

Read More 'PYXS' Stories Here

PYXS Price Returns

1-mo -1.43%
3-mo 122.07%
6-mo 194.51%
1-year 56.82%
3-year N/A
5-year N/A
YTD 168.33%
2023 34.33%
2022 -87.78%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!